INDUSTRY NEWS
PROSTATE AI TOOL RECEIVING CERTIFICATION AS MEDICAL PRODUCT
Artificial intelligence innovator FUSE-AI has received EU Medical Device Regulation (MDR) 2017/745 IIa certification for its AI software ‘
Prostate.Carcinoma.ai’. As of January this year, the company was authorised to distribute its software as a medical product. The product aids radiologists by
automatically segmenting the prostate gland in MRI scans and independently identifying pathological changes, promising a 30% time saving per patient. This efficiency translates into considerable financial benefits for radiological clinics and practices, fuelling strong interest in the deployment of the AI algorithm. “This AI software is a testament
to the interdisciplinary collaboration among scientists, AI developers, and radiologists. Receiving certification is a pivotal step, transitioning preliminary agreements into binding contracts and fully leveraging the software’s capabilities in clinical settings. This milestone substantially lowers investment risks into our company,” stated Matthias Steffen, Founder and CEO of FUSE-AI. This favourable development for
“
Prostate.Carcinoma.ai” coincides with a prediction that the global market for medical image analysis software will reach a value of $4.545 billion by end of FY 2023, with a Compound Annual Growth Rate (CAGR) of 9.9% according to
Reportlinker.com
BROKEN STRING BIOSCIENCES AND FRANCIS CRICK INSTITUTE TO COLLABORATE ON ALS RESEARCH
London-based genomics company Broken String Biosciences has entered a research collaboration with biomedical discovery institute the Francis Crick Institute to develop novel applications for Broken String’s proprietary DNA break-mapping platform, INDUCE-seq, beyond its established capabilities in gene- editing. The research will be focused on leveraging the technology to investigate the impact of genomic instability in the development of amyotrophic lateral sclerosis (ALS). ALS is a progressive and debilitating neurodegenerative disease, causing gradual loss of the ability to control voluntary movements and basic bodily functions. The collaboration is focused on
understanding the contribution of genome stability to ALS, combining the interests of Prof Simon Boulton and Dr Nishita Parnandi at the Crick Institute who are focused on genome stability and DNA double- strand break (DSB), with Prof Rickie Patani and Dr Giulia Tyzack who are interested in understanding the underlying mechanism of the ALS disease. Recognising the utility of the novel INDUCE-seq platform developed by Broken String’s R&D department,
the teams aim to collaborate to demonstrate and further validate the INDUCE-seq technology in this setting. The majority of ALS cases (90%)
are considered sporadic. While there has been progress to better understand the genes and biological markers associated with the disease, very little is understood about the causes, with current treatment strategies focused on symptom management and slowing disease progression. Combining world-leading research from the Crick with Broken String’s expertise in genomics, sequencing, and bioinformatics, the partnership provides a unique opportunity to expand application of the Company’s INDUCE-seq technology in a key area of clinical unmet need, to support improved diagnosis and treatment of ALS. The partnership has been secured
via the Francis Crick Institute’s Business Engagement Fund, a new initiative supported by The Medical Research Council (MRC- UKRI), designed to encourage collaborations with small-to- medium-sized enterprises (SMEs) and strengthen the Crick’s engagement with industry.
FUSE-AI has been authorised to distribute its software as a medical product
EARLY-ACCESS PROGRAM TO HELP WITH VIRAL VECTOR PRODUCTION
Leading provider of premium vector technology and services for the production of biologics ProteoNic Biosciences has launched its LV-2G UNic Early Access Program. This program marks a significant milestone in lentivirus manufacturing optimisation, according to the company, offering access to groundbreaking vector technology designed to revolutionise viral vector production. The product is aimed at CDMOs,
biotechs, and biopharmaceutical companies who would benefit from integrating this cutting- edge vector technology into their existing systems, paving the way for increased viral vector production capacity and substantial improvements in manufacturing cost efficiency. Frank Pieper, CEO of ProteoNic, said of the launch: “The LV-2G UNic Early Access Program will serve as a launching platform for our viral vector manufacturing innovation. By offering early access to our state-of-the- art vector technology, we empower researchers to unlock unprecedented levels of efficiency and productivity in viral vector manufacturing.”
www.scientistlive.com 7
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60
